Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 3;12(17):5355-5364.
doi: 10.7150/jca.60682. eCollection 2021.

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Chien-Ting Liu  1   2 , Meng-Che Hsieh  3   4 , Yu-Li Su  1   2 , Chaio-Ming Hung  4   5 , Sung-Nan Pei  3   4 , Chun-Kai Liao  1 , Yu-Fen Tsai  3   4 , Hsiu-Yun Liao  3 , Wei-Ching Liu  3 , Chong-Chi Chiu  4   5 , Shih-Chung Wu  6 , Shih-Ho Wang  2   6 , Ching-Ting Wei  7 , Kun-Ming Rau  3   4
Affiliations

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Chien-Ting Liu et al. J Cancer. .

Abstract

Advanced breast cancer (ABC) has become a chronic disease. In such a situation, an effective therapy with low toxicities and economically acceptable is needed. Metronomic vinorelbine (mVNR) has been proved to be effective on the control of MBC. The aim of this study is to evaluate the efficacy and safety of mVNR as the salvage therapy for patients with ABC. Oral vinorelbine (VNR) was administered at 70 mg/m2, fractionated on days 1, 3, and 5, for 3 weeks on and 1 week off. Once the mVNR was combined with trastuzumab, or was combined with bevacizumab, the schedule was changed to 2 weeks on and 1 week off. Clinical data of patients with ABC who had received treatment with mVNR and tumor characteristics were collected and analyzed. From Mar. 2013 to Dec, 2020, there were 90 patients with ABC received mVNR. The overall response rate was 53.3% and overall disease control rate (DCR) was 78.9% in this study, including 4 (4.4%) cases reached complete response, 44 (48.9%) cases reached partial response and 23 (25.6%) cases were table disease. The median time to treatment failure (TTF) of the Lumina A patients was 13.3 months, Lumina B patients was 9.1 months, Her-2 enrich patients was 8.9 months, and triple negative breast cancer (TNBC) patients was 5.6 months. Median overall survival time for Lumina A, Lumina B, Her-2 enrich and TNBC were 54.6 months, 53.3 months, 59.5 months and 24.5 months separately. Side effects were minimal and manageable. Metronomic VNR can be an effective treatment for ABC either works as a switch maintenance or salvage therapy. In combination with target therapy or hormonal therapy, mVNR can further improve TTF and DCR with minimal toxicities. Further study should focus on the optimal dosage, schedule and combination regimen.

Keywords: advanced breast cancer; effect.; metastatic breast cancer; metronomic chemotherapy; vinorelbine.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Time to treatment failure (A) and overall survival (B) of all 4 subgroups.
Figure 2
Figure 2
Time to treatment failure (A) and overall survival (B) of 3 groups.
Figure 3
Figure 3
Time to treatment failure (A) and overall survival (B) by response to previous treatment.
Figure 4
Figure 4
Time to treatment failure (A) and overall survival (B) by treatment linage of vinorelbine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kaklamani VG, Gradishar WJ. Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist. 2017;22(5):507–517. - PMC - PubMed
    1. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2(12):733–40. - PubMed
    1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–7. - PMC - PubMed
    1. Klement G, Baruchel S, Rak J. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105(8):R15–24. - PMC - PubMed
    1. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658):404–7. - PubMed